此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Efficacy and Safety of Pirfenidone Treatment in HPS-ILD (PEARL)

2019年12月6日 更新者:Jesse Roman

Pirfenidone in the Treatment of Hermansky Pudlak Syndrome (HPS) - Related Interstitial Lung Disease (ILD)

This research study will explore the safety and efficacy of the drug, pirfenidone, in patients with a diagnosis of Hermansky-Pudlak Syndrome (HPS) who have an associated interstitial lung disease (ILD) over a planned period of 56 weeks.

研究概览

详细说明

An open-label clinical study designed to evaluate the efficacy and safety of administering pirfeniodne for 52 weeks to subjects with HPS-ILD. Patients meeting the eligibility criteria without contraindications for the study will be provided pirfenidone 2403 mg/day. Efficacy will be evaluated through interval testing of pulmonary function tests, patient reported outcomes, adverse events and survival. Safety will be assessed by determining adverse events, hospitalizations, and all-cause mortality.

研究类型

介入性

注册 (预期的)

50

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Mayaguez、波多黎各、00680
        • Mayaguez Medical Center
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19107
        • Thomas Jefferson University

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Probable or definite diagnosis of HPS based on confirmed genetic mutation or clinical picture characterized by oculo-cutaneous albinism, bleeding disorder, and possible colitis and ILD.
  • Diagnosis of ILD supported by clinically indicated HRCT prior to Screening, and presence of fibrotic abnormality affecting more than 5% of the lung parenchyma, with or without traction bronchiectasis or honeycombing, on Screening
  • No features supporting an alternative diagnosis (e.g., infection)
  • Change in pre-bronchodilator FVC (measured in liters) between Screening (Visit 1) and

Baseline (Visit 2) must be a < 10% relative difference, calculated as:

100%*[absolute value (Screening FVC - Baseline FVC)/Screening FVC

  • Stable dose (at least three months at the time of Screening) of corticosteroids.
  • No cytotoxic, immunosuppresive agents, cytokine-modulating, or receptor antagonists agents are allowed (including but not limited to azathioprine, cyclophosphamide, cyclosporine, etanercept, iloprost, infliximab, methotrexate, mycophenolate mofetil, nintedanib, tacrolimus, tetrathiomolybdate, TNF-α inhibitors, rituximab, abatacept, tofacitintib, tociluzimab).
  • Able to understand and sign a written informed consent form

Exclusion Criteria:

  • Not a suitable candidate for enrollment or unlikely to comply with the requirements of this study, in the opinion of the investigator
  • Cigarette smoking within 3 months of Screening or unwilling to avoid tobacco products throughout the study
  • History of clinically significant environmental exposure known to cause pulmonary fibrosis (PF), including but not limited to drugs (such as amiodarone), asbestos, beryllium, radiation, and domestic birds
  • Concurrent presence of other interstitial lung disease, including but not limited to radiation, drug toxicity, sarcoidosis, hypersensitivity pneumonitis, bronchiolitis obliterans organizing pneumonia, human immunodeficiency virus (HIV), viral hepatitis, and cancer
  • Concurrent presence of other pleuropulmonary manifestations inconsistent with HPS- ILD
  • Presence of pleural effusion occupying more than 10% of the hemithorax on Screening HRCT
  • Clinical diagnosis of a connective tissue disease or overlap syndrome (including but not limited to rheumatoid arthritis, scleroderma, polymyositis/dermatomyositis, systemic lupus erythematosus)
  • Coexistent clinically significant COPD/emphysema or asthma in the opinion of the site principle investigator
  • Clinical evidence of active infection, including but not limited to bronchitis, pneumonia, sinusitis, urinary tract infection, or cellulitis
  • Any history of malignancy diagnosed within 5 years of screening, other than basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or low grade cervical carcinoma in situ.
  • History of severe hepatic impairment or end-stage liver disease
  • History of end-stage renal disease requiring dialysis
  • History of unstable or deteriorating cardiac or disease, myocardial infarction within the previous year, heart failure within the last 3 years, or cardiac arrhythmia requiring drug therapy
  • Any condition that, in the opinion of the investigator, might be significantly exacerbated by the known side effects associated with the administration of pirfenidone
  • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use two adequate methods of contraception, including at least one method with a failure rate of <1% per year, during the 52 weeks of treatment.

    1. A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus).
    2. Examples of contraceptive methods with a failure rate of <1% per year include bilateral tubal ligation, male sterilization, established and proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.
    3. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
  • For men who are not surgically sterile: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:

    1. With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 118 days after the last dose of pirfenidone.
    2. Men must refrain from donating sperm during this same period.
  • Investigational therapy, defined as any drug that has not been approved for marketing for any indication in the country of the participating site including pirfenidone, at the time of Screening
  • History of alcohol or substance abuse in the past 2 years, at the time of Screening
  • Family or personal history of long QT syndrome
  • Any of the following liver function test criteria above specified limits:

    1. Total bilirubin above the upper limit of normal (ULN), excluding patients with Gilbert's syndrome; aspartate or alanine aminotransferase (AST/SGOT or ALT/SGPT) >3 × ULN; alkaline phosphatase >2.5 × ULN
    2. Creatinine clearance (CrCl <30) mL/min, calculated using the Cockcroft-Gault formula
    3. Electrocardiogram (ECG) with a QTcB interval >500 msec at Screening
  • Prior use of pirfenidone or known hypersensitivity to any of the components of study treatment
  • Use of any of the following therapies within 28 days before Screening:

    1. Investigational therapy, defined as any drug that has not been approved for marketing for any indication in the country of the participating site
    2. Fluvoxamine
    3. Sildenafil (daily use). Note: intermittent use for erectile dysfunction is allowed

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Oral Pirfenidone 2403 mg per day
Enrolled subjects will receive oral pirfenidone 801 mg taken three times a day. Pirfenidone will be supplied in 267 mg capsules.
Pirfenidone will be titrated over 14 days, as tolerated, to the full dose of 2403 mg per day, as follows: Days 1 - 7: one capsule TID; Days 8 - 14: two capsules TID; Days 15 to week 52: three capsules TID. Dose may be reduced to manage an adverse event.
其他名称:
  • 埃斯布里特

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in Forced Vital Capacity (FVC)
大体时间:baseline, 6 months, 12 months
The incidence of decline in percent predicted FVC of 10 % or greater from baseline measured at 6 and 12 months
baseline, 6 months, 12 months

次要结果测量

结果测量
措施说明
大体时间
Change in Forced Vital Capacity (FVC)
大体时间:week 52
1. The Incidence of decline from baseline in percent predicted FVC of 10% or greater during the 52 week treatment period.
week 52
Change in Diffusion Capacity (DLCO)
大体时间:week 52
2. The Incidence of decline from baseline in percent predicted DLCO of 15% or greater during the 52 week treatment period.
week 52
Incidence of Treatment Emergent Adverse Events
大体时间:week 52
3. The number of participants with and number of treatment emergent adverse events reported by the participant will be collected.
week 52
Incidence of Treatment Emergent Serious Adverse Events
大体时间:week 52
4. The number of participants with and number of treatment-emergent serious adverse events reported by the participants will be collected.
week 52

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

合作者

调查人员

  • 首席研究员:Jesse Roman, MD、Thomas Jefferson University

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (预期的)

2019年12月1日

初级完成 (预期的)

2022年12月31日

研究完成 (预期的)

2022年12月31日

研究注册日期

首次提交

2019年11月6日

首先提交符合 QC 标准的

2019年12月6日

首次发布 (实际的)

2019年12月10日

研究记录更新

最后更新发布 (实际的)

2019年12月10日

上次提交的符合 QC 标准的更新

2019年12月6日

最后验证

2019年12月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅